002932 明德生物
2024/09 - 九个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)1.3591.19690.61472.64854.800
总资产报酬率 ROA (%)1.1390.90466.73958.35345.415
投入资产回报率 ROIC (%)1.3281.13484.56867.58535.171

边际利润分析
销售毛利率 (%)51.79554.27866.84675.01578.209
营业利润率 (%)36.46919.37148.24059.99758.626
息税前利润/营业总收入 (%)31.61719.35647.87659.67457.772
净利润/营业总收入 (%)27.6419.23541.60051.12349.591

收益指标分析
经营活动净收益/利润总额(%)-120.75021.010118.847100.88399.416
价值变动净收益/利润总额(%)101.30489.4560.7460.0400.235
营业外收支净额/利润总额(%)-5.388-3.792-0.068-0.192-1.002

偿债能力分析
流动比率 (X)3.2872.6983.2485.4953.937
速动比率 (X)3.1012.5713.1394.9743.556
资产负债率 (%)10.53614.81726.34916.59421.853
带息债务/全部投入资本 (%)0.9671.1316.9063.398--
股东权益/带息债务 (%)10,113.1298,631.6771,336.1842,821.838651.091
股东权益/负债合计 (%)818.273550.562268.294491.842353.403
利息保障倍数 (X)-10.58227.931-144.295-287.170-212.237

营运能力分析
应收账款周转天数 (天)1,263.348905.10256.38058.4840.000
存货周转天数 (天)309.424203.37427.998102.4270.000